These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30954934)

  • 1. Role of the purinergic P2X receptors in osteoclast pathophysiology.
    Jørgensen NR
    Curr Opin Pharmacol; 2019 Aug; 47():97-101. PubMed ID: 30954934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro.
    Gartland A; Buckley KA; Bowler WB; Gallagher JA
    Calcif Tissue Int; 2003 Oct; 73(4):361-9. PubMed ID: 12874700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors.
    Tanaka M; Hosoya A; Mori H; Kayasuga R; Nakamura H; Ozawa H
    J Bone Miner Metab; 2018 Jan; 36(1):54-63. PubMed ID: 28243795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of P2X receptors in bone biology.
    Jørgensen NR; Syberg S; Ellegaard M
    Curr Med Chem; 2015; 22(7):902-14. PubMed ID: 25515517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2X receptors and inflammation.
    Di Virgilio F
    Curr Med Chem; 2015; 22(7):866-77. PubMed ID: 25524252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists to TRPV1, ASICs and P2X have a potential role to prevent the triggering of regional bone metabolic disorder and pain-like behavior in tail-suspended mice.
    Hanaka M; Iba K; Dohke T; Kanaya K; Okazaki S; Yamashita T
    Bone; 2018 May; 110():284-294. PubMed ID: 29452264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of purinergic receptor polymorphisms in human bone.
    Wesselius A; Bours MJ; Agrawal A; Gartland A; Dagnelie PC; Schwarz P; Jorgensen NR
    Front Biosci (Landmark Ed); 2011 Jun; 16(7):2572-85. PubMed ID: 21622196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain.
    Wu JX; Xu MY; Miao XR; Lu ZJ; Yuan XM; Li XQ; Yu WF
    Eur J Pain; 2012 Nov; 16(10):1378-88. PubMed ID: 22528605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2X7 receptor acts as an efficient drug target in regulating bone metabolism system.
    Dong Y; Chen Y; Zhang L; Tian Z; Dong S
    Biomed Pharmacother; 2020 May; 125():110010. PubMed ID: 32187957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [P2 purinergic receptors: regulation of bone metabolism and therapeutic potential?].
    Solgaard M; Jørgensen NR
    Ugeskr Laeger; 2005 Aug; 167(34):3152-6. PubMed ID: 16117911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus.
    Henshall DC; Engel T
    Epilepsy Behav; 2015 Aug; 49():8-12. PubMed ID: 25843343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption.
    Togari A; Arai M
    J Pharmacol Sci; 2008 Apr; 106(4):542-6. PubMed ID: 18431037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of P2X receptors expressed in rat pulmonary arteries.
    Syed NI; Tengah A; Paul A; Kennedy C
    Eur J Pharmacol; 2010 Dec; 649(1-3):342-8. PubMed ID: 20868665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts.
    Korcok J; Raimundo LN; Ke HZ; Sims SM; Dixon SJ
    J Bone Miner Res; 2004 Apr; 19(4):642-51. PubMed ID: 15005852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purinergic P2X receptors: structural models and analysis of ligand-target interaction.
    Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R
    Eur J Med Chem; 2015 Jan; 89():561-80. PubMed ID: 25462266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis and inflammation.
    Lacativa PG; Farias ML
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):123-32. PubMed ID: 20485900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X and P2Y nucleotide receptors as targets in cardiovascular disease.
    Kennedy C; Chootip K; Mitchell C; Syed NI; Tengah A
    Future Med Chem; 2013 Mar; 5(4):431-49. PubMed ID: 23495690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of FGFR3 in Osteoclast Lineage Cells Results in Increased Bone Mass in Mice by Inhibiting Osteoclastic Bone Resorption.
    Su N; Li X; Tang Y; Yang J; Wen X; Guo J; Tang J; Du X; Chen L
    J Bone Miner Res; 2016 Sep; 31(9):1676-87. PubMed ID: 26990430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of temporomandibular joint P2X3 and P2X2/3 receptors in carrageenan-induced inflammatory hyperalgesia in rats.
    Teixeira JM; Oliveira MC; Nociti FH; Clemente-Napimoga JT; Pelegrini-da-Silva A; Parada CA; Tambeli CH
    Eur J Pharmacol; 2010 Oct; 645(1-3):79-85. PubMed ID: 20558155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
    Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
    Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.